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From the Latin bos (“ox” or “cow”) My-cobacterium bovis is a virulent bacterial 
species originally isolated from tubercules in 
cattle. Robert Koch, who discovered the tu-
bercle bacillus in 1882, believed that M. bovis 
was not a danger to humans. Theobald Smith 
and others established beyond doubt that, 
contrary to Koch’s belief, M. bovis could in-
fect humans but was not the usual source of 
human infection. In 1908, French scientists 
Albert Calmette and Camille Guérin chose an 
M. bovis strain for their work on a tuberculo-
sis vaccine. They repeatedly subcultured the 
isolate on a mixture of glycerol, potato, and 
bile for 13 years until it was sufficiently at-
tenuated to be used as a vaccine. The bacillus 
Calmette-Guérin (BCG) vaccine was adopted 
by the League of Nations as the standard tu-
berculosis vaccine in 1928 and continues to be 
used in most developing countries.
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